Literature DB >> 26397999

18F-FDG-PET/MR increases diagnostic confidence in detection of bone metastases compared with 18F-FDG-PET/CT.

Andrei Samarin1, Martin Hüllner, Marcelo A Queiroz, Paul Stolzmann, Irene A Burger, Gustav von Schulthess, Patrick Veit-Haibach.   

Abstract

PURPOSE: The aim of this study was to compare detection, lesion conspicuity and reader confidence of F-fluorodeoxyglucose (F-FDG)-PET/MR and F-FDG-PET/computed tomography (CT) in patients with F-FDG avid bone metastases.
MATERIALS AND METHODS: In this prospective study, a total of 30 PET/CT and PET/MRI data sets were performed in 24 patients. Each examination was evaluated for the presence of PET-positive bone lesions consistent with metastatic involvement. Conspicuity of PET-positive bone lesions was evaluated on the corresponding PET/CT and PET/MR images and compared using the Wilcoxon signed-ranks test. Reader confidence was determined to evaluate whether PET/CT or PET/MR was more useful for the assessment of the bone metastases and was compared using Student's t-test.
RESULTS: Overall, in both examinations, PET/CT and PET/MRI detected 86 F-FDG-positive bone lesions. On all 30 PET/MRI examinations, at least one morphological correlate for F-FDG-positive bone lesions was found on the MR component (82 out of 86 lesions). PET/CT imaging allowed identification of corresponding structural changes on the CT component in 23 out of 30 studies (65 out of 86 lesions). In lesion-by-lesion analysis, the mean lesion conspicuity was significantly better on T1 fat MR imaging compared with CT imaging (P=0.005). In seven out of 30 studies, a significant increase in reader confidence of PET/MRI compared with PET/CT was found.
CONCLUSION: PET/MRI offers higher reader confidence and improved conspicuity in bone metastases compared with PET/CT. However, the overall detection rate was not different. The highest possible clinical impact of PET/MRI appears to be in patients with limited, early bone metastatic disease.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26397999     DOI: 10.1097/MNM.0000000000000387

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  10 in total

1.  PET/MRI and PET/CT: is there room for both at the top of the food chain?

Authors:  Torsten Kuwert; Philipp Ritt
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-19       Impact factor: 9.236

2.  Fast non-enhanced abdominal examination protocols in PET/MRI for patients with neuroendocrine tumors (NET): comparison to multiphase contrast-enhanced PET/CT.

Authors:  Ferdinand Seith; Christina Schraml; Gerald Reischl; Konstantin Nikolaou; Christina Pfannenberg; Christian la Fougère; Nina Schwenzer
Journal:  Radiol Med       Date:  2018-06-30       Impact factor: 3.469

3.  Integrated versus separate reading of F-18 FDG-PET/CT and MRI for abdominal malignancies - effect on staging outcomes and diagnostic confidence.

Authors:  Lisa A Min; Wouter V Vogel; Max J Lahaye; Monique Maas; Maarten L Donswijk; Erik Vegt; Miranda Kusters; Henry J Zijlmans; Katarzyna Jóźwiak; Sander Roberti; Regina G H Beets-Tan; Doenja M J Lambregts
Journal:  Eur Radiol       Date:  2019-05-22       Impact factor: 5.315

Review 4.  FDG Whole-Body PET/MRI in Oncology: a Systematic Review.

Authors:  Hyun Woo Kwon; Ann-Katharina Becker; Jin Mo Goo; Gi Jeong Cheon
Journal:  Nucl Med Mol Imaging       Date:  2016-04-07

5.  [Expert Consensus on the Diagnosis and Treatment of Bone Metastasis in Lung Cancer (2019 Version)].

Authors: 
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2019-04-20

6.  [Bone tumors and metastases: tips for initial diagnosis and follow-up : Update 2019].

Authors:  Kolja M Thierfelder; Sophie Niendorf; Judith S Gerhardt; Marc-An Dré Weber
Journal:  Radiologe       Date:  2020-02       Impact factor: 0.635

Review 7.  Applications of PET-MRI in musculoskeletal disease.

Authors:  Feliks Kogan; Stephen M Broski; Daehyun Yoon; Garry E Gold
Journal:  J Magn Reson Imaging       Date:  2018-07       Impact factor: 4.813

8.  What is the Diagnostic Performance of 18F-FDG-PET/MRI in the Detection of Bone Metastasis in Patients with Breast Cancer?

Authors:  Filiz Çelebi
Journal:  Eur J Breast Health       Date:  2019-10-01

9.  An international expert opinion statement on the utility of PET/MR for imaging of skeletal metastases.

Authors:  Jad S Husseini; Bárbara Juarez Amorim; Angel Torrado-Carvajal; Vinay Prabhu; David Groshar; Lale Umutlu; Ken Herrmann; Lina García Cañamaque; José Ramón García Garzón; William E Palmer; Pedram Heidari; Tiffany Ting-Fang Shih; Jacob Sosna; Cristina Matushita; Juliano Cerci; Marcelo Queiroz; Valdair Francisco Muglia; Marcello H Nogueira-Barbosa; Ronald J H Borra; Thomas C Kwee; Andor W J M Glaudemans; Laura Evangelista; Marco Salvatore; Alberto Cuocolo; Andrea Soricelli; Christian Herold; Andrea Laghi; Marius Mayerhoefer; Umar Mahmood; Ciprian Catana; Heike E Daldrup-Link; Bruce Rosen; Onofrio A Catalano
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-22       Impact factor: 9.236

10.  Are Gadolinium-Enhanced MR Sequences Needed in Simultaneous 18F-FDG-PET/MRI for Tumor Delineation in Head and Neck Cancer?

Authors:  N Pyatigorskaya; R De Laroche; G Bera; A Giron; C Bertolus; G Herve; E Chambenois; S Bergeret; D Dormont; M Amor-Sahli; A Kas
Journal:  AJNR Am J Neuroradiol       Date:  2020-09-24       Impact factor: 4.966

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.